Misonix, Inc. To Report Financial Results For The Fourth Quarter And Fiscal Year 2013 On Tuesday, September 24, 2013

 Misonix, Inc. To Report Financial Results For The Fourth Quarter And Fiscal
                   Year 2013 On Tuesday, September 24, 2013

Conference call to be conducted at 4:30 pm ET

PR Newswire

FARMINGDALE, N.Y., Sept. 18, 2013

FARMINGDALE,N.Y., Sept. 18, 2013 /PRNewswire/ -- Misonix, Inc.
(Nasdaq:MSON), an international surgical device company that designs,
manufactures and markets innovative therapeutic ultrasonic products for spine
surgery, skull based surgery, neurosurgery, wound debridement, cosmetic
surgery, laparoscopic surgery and other surgical applications, announced today
that it will report financial results for the fourth quarter and fiscal year
2013 ended June 30, 2013 on Tuesday, September 24, 2013. The Company has
scheduled a conference call that same day, Tuesday, September 24, 2013, at
4:30 pm ET to review the results.

Interested parties can access the conference call by dialing (877) 317-6789 or
(412) 317-6789 or can listen via a live Internet webcast, which is available
in the Investor Relations section of the Company's website at

A teleconference replay of the call will be available for three days at (877)
344-7529 or (412) 317-0088, confirmation # 10033492. A webcast replay will be
available in the Investor Relations section of the Company's website at
www.misonix.com for 30 days.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at

Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

Company Contact:​  Investor Contacts:
Richard Zaremba    Robert Blum, Joe Dorame, Joe Diaz
Misonix, Inc.      Lytham Partners, LLC
631-694-9555       602-889-9700
invest@misonix.com mson@lythampartners.com
www.misonix.com    www.lythampartners.com

SOURCE Misonix, Inc.

Website: http://www.misonix.com
Press spacebar to pause and continue. Press esc to stop.